ACTT

Sponsor: NIH-NIAID Primary Objective: to evaluate the clinical efficacy, as assessed by time to recovery, of different investigational therapeutics as compared to the control arm First NIH trial for the treatment of COVID-19. 

ACTT 1 Conducted March-April 2020; Remdesivir vs placebo; Remdesivir approved by FDA from ACTT 1 data.   Study publications: Remdesivir for the Treatment of Covid-19—Final Report, N Engl J Med. 2020 Nov 5;383:1813-1826;

            ACTT 2 Conducted May-July 2020 Remdesivir plus Baricitinib/Placebo UT Health San Antonio/University Hospital was the highest enrolling site globally   Study publications: Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , N Engl J Med. 2020 Dec 11:NEJMoa2031944

            ACTT 3 Conducted Aug-Dec 2020 Remdesivir plus Interferon/Placebo Study publication: Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Dec;9(12):1365-1376. doi: 10.1016/S2213-2600(21)00384-2. Epub 2021 Oct 18.

            ACTT 4 Conducted Dec 2020-April 2021 Remdesivir plus Baricitinib vs Dexamethasone. Study publication: Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial Lancet Respir Med. 2022 Sep;10(9):888-899. doi: 10.1016/S2213-2600(22)00088-1. Epub 2022 May 23.

Meet Your Clinical Research Team